Managing Patients with FMF Diagnosis of FMF depends on the clinical assessments, confirmed by molecular testing. However, a significant proportion of heterozygotes also express the phenotype. Despite the fact that the heterozygotes have a tendency to have a relatively mild disease, the disease couldn't be recognized from that of homozygous patients and that FMF could be seen as a dominant condition with low penetrance in some cases. Heterozygous FMF patients may benefit from a trial of colchicine for six months and individuals who respond to colchicine will be considered FMF patients. Following up the of the patients by annual physical examination, urine spot test for protein, and evaluation for hematuria for all affected individuals including those treated with colchicine; consider monitoring of acute-phase reactants (ESR and fibrinogen levels) at regular intervals during the attack-free periods. Evaluation of relatives at risk by offering molecular genetic testing to all first-degree relatives and other family members (regardless of symptoms) as renal amyloidosis can be avoided by early diagnosis and colchicine treatment.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Vendeur : Meadowland Media, Fayetteville, AR, Etats-Unis
paperback. SHIPS DAILY WITH FREE TRACKING! N° de réf. du vendeur A133-021926-LLU-203X5
Quantité disponible : 1 disponible(s)
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Managing Patients with FMF Diagnosis of FMF depends on the clinical assessments, confirmed by molecular testing. However, a significant proportion of heterozygotes also express the phenotype. Despite the fact that the heterozygotes have a tendency to have a relatively mild disease, the disease couldn't be recognized from that of homozygous patients and that FMF could be seen as a dominant condition with low penetrance in some cases. Heterozygous FMF patients may benefit from a trial of colchicine for six months and individuals who respond to colchicine will be considered FMF patients. Following up the of the patients by annual physical examination, urine spot test for protein, and evaluation for hematuria for all affected individuals including those treated with colchicine; consider monitoring of acute-phase reactants (ESR and fibrinogen levels) at regular intervals during the attack-free periods. Evaluation of relatives at risk by offering molecular genetic testing to all first-degree relatives and other family members (regardless of symptoms) as renal amyloidosis can be avoided by early diagnosis and colchicine treatment. 72 pp. Englisch. N° de réf. du vendeur 9786200225047
Quantité disponible : 2 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Taschenbuch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Managing Patients with FMF Diagnosis of FMF depends on the clinical assessments, confirmed by molecular testing. However, a significant proportion of heterozygotes also express the phenotype. Despite the fact that the heterozygotes have a tendency to have a relatively mild disease, the disease couldn't be recognized from that of homozygous patients and that FMF could be seen as a dominant condition with low penetrance in some cases. Heterozygous FMF patients may benefit from a trial of colchicine for six months and individuals who respond to colchicine will be considered FMF patients. Following up the of the patients by annual physical examination, urine spot test for protein, and evaluation for hematuria for all affected individuals including those treated with colchicine; consider monitoring of acute-phase reactants (ESR and fibrinogen levels) at regular intervals during the attack-free periods. Evaluation of relatives at risk by offering molecular genetic testing to all first-degree relatives and other family members (regardless of symptoms) as renal amyloidosis can be avoided by early diagnosis and colchicine treatment. N° de réf. du vendeur 9786200225047
Quantité disponible : 1 disponible(s)
Vendeur : moluna, Greven, Allemagne
Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: T. El-Bassyouni HalaHala T. El Bassyouni, Professor of Clinical Genetics, National Research Centre, Egypt. She published 100 articles participated in 15 projects and attended several international conferences. She teached in Scienti. N° de réf. du vendeur 300820561
Quantité disponible : Plus de 20 disponibles
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Paperback. Etat : Brand New. 72 pages. 8.66x5.91x0.17 inches. In Stock. N° de réf. du vendeur zk6200225044
Quantité disponible : 1 disponible(s)
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -Managing Patients with FMF Diagnosis of FMF depends on the clinical assessments, confirmed by molecular testing. However, a significant proportion of heterozygotes also express the phenotype. Despite the fact that the heterozygotes have a tendency to have a relatively mild disease, the disease couldn't be recognized from that of homozygous patients and that FMF could be seen as a dominant condition with low penetrance in some cases. Heterozygous FMF patients may benefit from a trial of colchicine for six months and individuals who respond to colchicine will be considered FMF patients. Following up the of the patients by annual physical examination, urine spot test for protein, and evaluation for hematuria for all affected individuals including those treated with colchicine; consider monitoring of acute-phase reactants (ESR and fibrinogen levels) at regular intervals during the attack-free periods. Evaluation of relatives at risk by offering molecular genetic testing to all first-degree relatives and other family members (regardless of symptoms) as renal amyloidosis can be avoided by early diagnosis and colchicine treatment.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 72 pp. Englisch. N° de réf. du vendeur 9786200225047
Quantité disponible : 1 disponible(s)
Vendeur : preigu, Osnabrück, Allemagne
Taschenbuch. Etat : Neu. Management of Familial Mediterranean Fever: Review of literature | Hala T. El-Bassyouni (u. a.) | Taschenbuch | 72 S. | Englisch | 2019 | LAP LAMBERT Academic Publishing | EAN 9786200225047 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu. N° de réf. du vendeur 116941678
Quantité disponible : 5 disponible(s)